期刊文献+

胆固醇修饰的非天然HR序列肽类HIV-1融合抑制剂的合成及活性初筛 被引量:3

Synthesis of Cholesterol Conjugated Non-native Derived Heptad Repeat Sequence Peptides as Potent HIV-1 Fusion Inhibitors
下载PDF
导出
摘要 将胆固醇分子通过1个半胱氨酸侧链硫醚键和1个β-丙氨酸连接臂引入到所设计的非天然HR序列抗HIV融合活性多肽的C端和N端,合成了与天然C肽序列同源性很低的非天然序列的类肽抗HIV融合分子,以考察胆固醇修饰对非天然HR序列活性的影响,探讨克服耐药性的新思路.生物活性评价结果表明,胆固醇与HR肽C端结合物抑制HIV融合活性显著提高,而连接到N端的序列则完全失去了抗病毒活性,表明所设计的非天然序列确实具有与天然序列类似的作用机制. As addition ot a cholesterol group to nature peptide fusion inhibitor can dramatically increase its antiviral potency, we designed and synthesized a series of cholesterol conjugated artificial peptide with low sequence homologous from HIV-1 gp41 as HIV-1 fusion inhibitors. The cholesterol moiety was introduced into C- or N-terminal of the peptide through a thioether in cysteine side chain and a/3-alanine linker to study the effect of cholesterol modification to the activity of non-natural HR sequence and explore new method to over- come the problem of HIV drug resistance. Cell-cell fusion assays showed that the fusion inhibitory activity of the C-terminal cholesterol conjugated peptide was significantly increased, while the activity of N-terminal con- jugated peptide was completely lost, consistent with the reported peptide conjugation using native peptide sequence, indicated that the designed non-natural sequences had a similar mechanism of action with natural sequences. This work provided a useful base for further drug optimization and discovery of highly active non- natural peptide sequences.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2014年第12期2542-2546,共5页 Chemical Journal of Chinese Universities
基金 国家自然科学基金(批准号:81373266) '重大新药创制'科技重大专项项目(批准号:2012ZX09301003)资助~~
关键词 HIV融合抑制剂 多肽 耐药性 非天然序列 HIV fusion inhibitor Peptide Drug resistance Non-natural sequence
  • 相关文献

参考文献21

  • 1Chan D. C. , Fass D. , Berger J. M. , Kim P. S. , Cell, 1997,89(2),263-273. 被引量:1
  • 2Lu M. , Blacklow S. C. , Kim P. S. , Nat. Struct. Biol. , 1995, 2 (12) , 1075-1082. 被引量:1
  • 3Melikyan G. B. , Markosyan R. M. , Hemmati H. , Delmedico M. K. , Lambert D. M. , Cohen F. S. , J. Cell Bioi. ,2000,151(2), 413-423. 被引量:1
  • 4Kliger Y. , Gallo S. A. , Peisajovich S. G. , Munoz-Barroso J. , Avkin S. , Blumenthal R. , Shai Y. , J. Biol. Chem. , 2001, 276(2) , 1391-1397. 被引量:1
  • 5Kaushik-Basu N. , Basu A. , Harris D. , BioDrugs, 2008, 22(3),161-175. 被引量:1
  • 6Wei X. , Decker J. M. , Liu H. , Zhang Z. , Arani R. B. , Kilby 1. M. , Saag M. S. , Wu X. , Shaw G. M. , Kappes J. C. , Antimicrob. Agents Chemother. , 2002, 46, 1896-1905. 被引量:1
  • 7Greenberg M. L. , Cammack N. , J. Antimicrob. Chemother. , 2004, 54, 333-340. 被引量:1
  • 8Xu L. , Pozniak A. , Wildfire A. , Stanfield-Oakley S. A. , Mosier S. M. , Ratcliffe D. , Workman J. , Joall A. , Myers R. , Smit E. , Cane P. A., Greenberg M. L., Pillay D., Antimicrob. Agents Chemother., 2005, 49,1113-1119. 被引量:1
  • 9Perez-Alvarez L , Carmona R. , Ocampo A. , Asorey A. , Miralles C. , Perez C. , Pinilla M. , Contreras G. , Taboada J. A. , Najera R. , J. Med. Virol., 2006, 78, 141-147. 被引量:1
  • 10凌彦博,王昆,姜喜凤,蔡利锋,刘克良.二价HIV-1融合抑制剂的设计、合成与活性评价[J].高等学校化学学报,2013,34(9):2102-2107. 被引量:3

二级参考文献20

  • 1Shao B. S., Gong W. H., Gao J. L., Shen W. P., Grimm M. C., Deng X. Y., Murphy P. M., Oppenheim J. J., Wang J. M., Blood, 1999, 3(11), 3885-3892. 被引量:1
  • 2Blower S. M., Aschenbach A. N., Gershengorn H. B., Kahn J. O., Nat. Med., 2001, 7(9), 1016-1020. 被引量:1
  • 3Ketas T. J., Frank I., Klasse P. J., Sullivan B. M., Gardner J. P., Spenlehauer C., Nesin M., Olson W. C., Moore J. P., Pope M., J. Virol., 2003, 77 (4), 2762-2767. 被引量:1
  • 4Alam S. M., Paleos C. A., Liao H. X., Scearce R., Robinson J., Haynes B. F., AIDS Res. Hum. Retroviruses, 2004, 20(5), 836-845. 被引量:1
  • 5Cai L. F., Jiang S. B., Chem. Med. Chem., 2010, 5(11), 1813-1824. 被引量:1
  • 6Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., Fujii N., Angew. Chem. Int. Ed., 2002, 41(16), 2937-2940. 被引量:1
  • 7Chen C. H., Greenberg M. L., Bolognesi D. P., Matthew T. J., AIDS Res. Hum. Retroviruses, 2000, 16(7), 2037-2041. 被引量:1
  • 8Cleveland S. M., McLain L., Cheung L., Jones T. D., Hollier M., Dimmock J., J. Gen. Virol., 2003, 84(13), 591-602. 被引量:1
  • 9Zhou J. M., Zhang Z. X., Mi Z. Y., Wang X., Zhang Q., Li Z. Y., Liang C., Cen S., Biochem., 2012, 51(6), 1288-1296. 被引量:1
  • 10Carmona R., Pérez-Alvarez L., Mu?oz M., Casado G., Delgado E., Sierra M., J. Clin. Virol., 2005, 32(7), 248-253. 被引量:1

共引文献2

同被引文献50

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部